EMA’s CHMP rejects approval of multiple sclerosis drug Nerventra
The two firms said they are committed to the Nerventra clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential
The two firms said they are committed to the Nerventra clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential
According to the company the dose counter is designed to help asthma patients, as well as their caregivers to keep track of the number of doses remaining in
According to reports, New York-based Pfizer could announce its decision to walk out of its bid. Under the acquisition rules in the UK, Pfizer can resume negotiations after
Dalvance is the first and only IV antibiotic approved to treat ABSSSI with a two-dose regimen of 1000mg followed one week later by 500mg, each administered over 30
As part of the deal, both the firms will jointly carry out a study titled ‘Development and Validation of a Human Brown Adipose Cell Model’, which will seek
The company is mainly focused on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related conditions. Patient enrolment
The approval of the drug is for patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following – splenomegaly, hepatomegaly,
The investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without RBV (weight-based),
The company intends to use the facility to manufacture investigational exon skipping therapies for Duchenne muscular dystrophy (DMD). The transaction, which includes about $25m in acquisition costs and
The positive opinion of the CHMP is for both kidney and liver transplant recipients and includes both the de novo transplant and switch settings, as well as for